[1]李萌 周雅奇 付真彦.SGLT2i对脂蛋白代谢作用及临床意义的讨论[J].心血管病学进展,2025,(6):520.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.010]
　LI Meng,ZHOU Yaqi,FU Zhenyan.Discussion of the Effects of SGLT2i on Lipoprotein Metabolism and Clinical Implications[J].Advances in Cardiovascular Diseases,2025,(6):520.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.010]
点击复制

SGLT2i对脂蛋白代谢作用及临床意义的讨论()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年6期
页码:
520
栏目:
综述
出版日期:
2025-06-25

文章信息/Info

Title:
Discussion of the Effects of SGLT2i on Lipoprotein Metabolism and Clinical Implications
作者:
李萌 周雅奇 付真彦
(新疆医科大学第一附属医院 冠心病二科,新疆 乌鲁木齐 830054)
Author(s):
LI Meng; ZHOU Yaqi; FU Zhenyan
(Department of Coronary Artery Disease,The First Affiliated Hospital of Xinjiang Medical University,Urumqi,Xinjiang 830054,China)
关键词:
糖尿病; 钠-葡萄糖共转运蛋白2抑制剂; 血脂
Keywords:
Diabetes mellitus;  Sodium-glucose cotransporter protein 2 inhibitor;  Plasma lipid
DOI:
10.16806/j.cnki.issn.1004-3934.2024.06.010
摘要:
钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）作为一种新型降血糖药，因其能够降低主要不良心血管事件的发生率，改善肾脏结局，减少心力衰竭住院率和死亡风险而备受关注。然而，SGLT2i并非在所有心血管事件中均获益，例如其对于总体人群的心肌梗死发生率影响并不显著，对卒中风险也没有影响。一个有趣的假设是，SGLT2i对心血管危险因素的影响能力可能有限，尤其涉及其对血脂代谢的作用。虽然目前关于SGLT2i对血脂影响仍存在争议，但绝大多数研究表明，服用该药物后，总胆固醇、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇均有所升高，而甘油三酯降低了。因此，现主要结合相关研究，讨论SGLT2i对血脂代谢的影响及其可能带来的临床意义。
Abstract:
Sodium-glucose cotransporter 2 inhibitors (SGLT2i),novel hypoglycemic agents,have attracted attention for their ability to reduce the incidence of major adverse cardiovascular events,improve renal outcomes,and reduce the risk of heart failure hospitalization and death. However,SGLT2i do not benefit all cardiovascular events; for example,their effect on the incidence of myocardial infarction in the overall population was not significant,nor did they have an effect on stroke risk. An interesting hypothesis is that SGLT2i may have a limited ability to influence cardiovascular disease risk factors,particularly with regard to their effects on lipid metabolism. Although there is still controversy regarding the effects of SGLT2i on plasma lipids,the vast majority of studies have shown an increase in total cholesterol,LDL cholesterol,and HDL cholesterol,and a decrease in triglycerides after administration of the drug. Therefore,this review will discuss the effects of SGLT2i on lipid metabolism and their possible clinical implications,mainly in the context of existing relevant studies

参考文献/References:

[1] American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management:Standards of Care in Diabetes-2024[J]. Diabetes Care,2024,47(Suppl 1):S179-S218.

[2] Rosengren A,Dikaiou P. Cardiovascular outcomes in type 1 and type 2 diabetes[J]. Diabetologia,2023,66(3):425-437.

[3] Young CF,Farnoudi N,Chen J,et al. Exploring SGLT-2 inhibitors:benefits beyond the glucose-lowering effect—What is new in 2023?[J]. Endocrines,2023,4(3):630-655.

[4] Li M,Yi T,Fan F,et al. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure:a systematic review and meta-analysis[J]. Cardiovasc Diabetol,2022,21(1):139.

[5] Bailey CJ,Day C,Bellary S. Renal protection with SGLT2 inhibitors:effects in acute and chronic kidney disease[J]. Curr Diab Rep,2022,22(1):39-52.

[6] Patel SM,Kang YM,Im K,et al. Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes:a SMART-C collaborative meta-analysis[J]. Circulation,2024,149(23):1789-1801.

[7] Bechmann LE,Emanuelsson F,Nordestgaard BG,et al. SGLT2-inhibition increases total,LDL,and HDL cholesterol and lowers triglycerides:Meta-analyses of 60 randomized trials,overall and by dose,ethnicity,and drug type[J]. Atherosclerosis,2024,394:117236.

[8]Katsuyama H,Hamasaki H,Adachi H,et al. Effects of sodium-glucose cotransporter 2 inhibitors on metabolic parameters in patients with type 2 diabetes: a chart-based analysis[J]. J Clin Med Res,2016,8(3): 237-243.

[9] Matthews DR. Sodium-glucoseco-transporter-2 inhibitors:a paradigm shift in treatment for type 2 diabetes[J]. Diabetes Obes Metab,2024,26 Suppl 5:3-4.

[10]Sarafidis PA,Tsapas A. Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J]. New Engl J Med,2016,374(11):1092.

[11]Neal B,Perkovic V,Mahaffey KW,et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. New Engl J Med,2017,377(7):644-657.

[12] Wiviott SD,Raz I,Bonaca MP,et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. New Engl J Med,2019,380(4):347-357.

[13]Cannon CP,Pratley R,Dagogo-Jack S,et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes[J]. New Engl J Med,2020,383(15):1425-1435.

[14]Salvatore T,Galiero R,Caturano A,et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors[J]. Int J Mol Sci,2022,23(7):3651.

[15]Marx N,Federici M,Schütt K,et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes[J]. Eur Heart J,2023,44(39):4043-4140.

[16]James S,Erlinge D,Storey RF,et al. Dapagliflozin in myocardial infarction without diabetes or heart failure[J]. NEJM Evid,2024,3(2):EVIDoa2300286.

[17] Butler J,Jones WS,Udell JA,et al. Empagliflozin after acute myocardial infarction[J]. New Engl J Med,2024,390(16):1455-1466.

[18]Osto E,Bonacina F,Pirillo A,et al. Neutral effect of SGLT2 inhibitors on lipoprotein metabolism:from clinical evidence to molecular mechanisms[J]. Pharmacol Res,2023,188:106667.

[19]Kwak SH,Han KA,Kim KS,et al. Efficacy and safety of enavogliflozin,a novel SGLT2 inhibitor,in Korean people with type 2 diabetes:a 24-week,multicentre,randomized,double-blind,placebo-controlled,phase III trial[J]. Diabetes Obes Metab,2023,25(7):1865-1873.

[20]Calapkulu M,Cander S,Gul OO,et al. Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center[J]. Diabetes Metab Syndr,2019,13(2):1031-1034.

[21]Li J,Li C,Feng X,et al. SGLT2 inhibition,blood lipids,and cardiovascular disease:a Mendelian randomization study[J]. ESC Heart Fail,2024,11(6):3960-3971.

[22]Talebi SS,Rezaie S,Hajmiri MS,et al. Comparison of the effects of empagliflozin and sitagliptin,as add-on to metformin,on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus[J]. Naunyn Schmiedebergs Arch Pharmacol,2024,397(11):9149-9165.

[23]Chen L,Chen S,Bai X,et al. Low-density lipoprotein cholesterol,cardiovascular disease risk,and mortality in China[J]. JAMA Netw Open,2024,7(7):e2422558.

[24]Stanciulescu LA,Scafa-Udriste A,Dorobantu M. Exploring the association between low-density lipoprotein subfractions and major adverse cardiovascular outcomes-a comprehensive review[J]. Int J Mol Sci,2023,24(7):6669.

[25]Hayashi T,Fukui T,Nakanishi N,et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes:comparison with sitagliptin[J]. Cardiovasc Diabetol,2017,16(1):8.

[26]Rau M,Thiele K,Korbinian Hartmann NU,et al. Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes:data from a randomized,placebo-controlled study[J]. Atherosclerosis,2021,330:8-13.

[27]Bouter KEC,van Bommel EJM,Jansen H,et al. The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol[J]. Diabetes Obes Metab,2020,22(6):988-996.

[28]Ference BA,Kastelein JJP,Ray KK,et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease[J]. JAMA,2019,321(4):364-373.

[29]Zahger D,Schwartz GG,Du W,et al. Triglyceride levels,alirocumab treatment,and cardiovascular outcomes after an?acute?coronary syndrome[J]. J Am Coll Cardiol,2024,84(11):994-1006.

[30]Sawada T,Uzu K,Hashimoto N,et al. Empagliflozin’s ameliorating effect on plasma triglycerides:association with endothelial function recovery in diabetic patients with coronary artery disease[J]. J Atheroscler Thromb,2020,27(7):644-656.

[31]Nicholls SJ,Nelson AJ. CETP Inhibitors:should we continue to pursue this pathway?[J]. Curr Atheroscler Rep,2022,24(12):915-923.

[32]Rohatgi A,Westerterp M,von Eckardstein A,et al. HDL in the 21st century:a multifunctional roadmap for future HDL research[J]. Circulation,2021,143(23):2293-2309.

[33]Ishibashi T,Kaneko H,Matsuoka S,et al. HDL cholesterol and clinical outcomes in diabetes mellitus[J]. Eur J Prev Cardiol,2023,30(8):646-653.

[34]Li J,Yu Y,Sun Y,et al. SGLT2 inhibition,circulating metabolites,and atrial fibrillation:a Mendelian randomization study[J]. Cardiovasc Diabetol,2023,22(1):278.

[35]Zhao Q,Wang J,Miao Z,et al. A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease[J]. Elife,2021,10:e58361.

[36]Gomez-Delgado F,Raya-Cruz M,Katsiki N,et al. Residual cardiovascular risk:when should we treat it?[J]. Eur J Intern Med,2024,120:17-24.

[37]Lin M,Shan Y,Hu X,et al. Short term effects of sodium-glucose cotransporter 2 inhibitors on lipid regulation in coronary artery disease patients undergoing Percutaneous Coronary Intervention:A Propensity-Matched Analysis[A]. Research Square,2022.

[38]Lund SS,Sattar N,Salsali A,et al. Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes:a post hoc analysis of pooled data from four phase 3 randomized clinical trials[J]. Diabetes Obes Metab,2021,23(12):2763-2774.

[39]Yaribeygi H,Maleki M,Reiner ?,et al. Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in diabetic milieu[J]. J Clin Med,2022,11(21):6544.

相似文献/References:

[1]张若愚,综述,殷跃辉,等.2型糖尿病及其药物对心房颤动的影响[J].心血管病学进展,2016,(4):337.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.003]
　ZHANG Ruoyu,YIN Yuehui.Effect of Type 2 Diabetes Mellitus and Diabetic Drugs on Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):337.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.003]
[2]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
　HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(6):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[3]夏熠 刘飞 夏云龙.糖尿病合并心房颤动的相关研究进展[J].心血管病学进展,2020,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
　XIA YiLIU FeiXIA Yunlong.Research Progress in Diabetes Mellitus Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(6):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
[4]菲尔凯提·玉山江李昊穆叶赛·尼加提.射血分数保留性心力衰竭合并糖尿病的研究进展[J].心血管病学进展,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
　FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(6):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
[5]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
　MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(6):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[6]张明 王敬萍.Nur77和GRP78与糖尿病心肌缺血再灌注损伤的关系研究[J].心血管病学进展,2020,(6):571.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.003]
　ZHANG Ming Wang Jingping.Relationship between Nur77 and GRP78 and Myocardial Ischemia-reperfusion Injury in Diabetic Patients[J].Advances in Cardiovascular Diseases,2020,(6):571.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.003]
[7]麦尔耶姆·瓦热斯 罗心平 周鹏.糖尿病与心力衰竭：2型糖尿病是心力衰竭的独立危险因素？[J].心血管病学进展,2020,(7):681.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.002]
　Maieryemu·Waresi,LUO Xinping,ZHOU Peng.Diabetes and Heart Failure: Is Type 2 Diabetes an Independent Risk Factor for Heart Failure?[J].Advances in Cardiovascular Diseases,2020,(6):681.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.002]
[8]廖丽萍 周跟东 张晓红.血清甘油三酯葡萄糖乘积指数与代谢性疾病的研究进展[J].心血管病学进展,2020,(11):1189.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[9]马赛 左庆娟 张国瑞 郭艺芳.钠氢交换体可能是钠-葡萄糖共转运蛋白-2抑制剂心力衰竭获益及不良反应的潜在靶点[J].心血管病学进展,2021,(8):686.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.004]
　MA Sai,ZUO Qingjuan,ZHANG Guorui,et al.Na+/H+?Exchanger:The?Potential?Target?for?the?Benefits?and?Adverse?Effects?of?Sodium-glucose?Co-Transporter?2?Inhibitors?in?Heart?Failure[J].Advances in Cardiovascular Diseases,2021,(6):686.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.004]
[10]高婧晗 刘飞 杨晓蕾 夏云龙.钙离子稳态的调控在糖尿病相关心房颤动中的作用[J].心血管病学进展,2021,(10):888.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.006]
　GAO Jinghan,LIU Fei,YANG Xiaolei,et al.Regulation of Calcium Homeostasis in Diabetes-Related Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(6):888.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.006]

更新日期/Last Update: 2025-07-31